Information de reference pour ce titreAccession Number: | 01445483-201807000-00015.
|
Author: | Donaghy, Paul C. PhD *,1; Firbank, Michael J PhD 1; Thomas, Alan J. PhD 1; Lloyd, Jim PhD 2; Petrides, George MBBS 2; Barnett, Nicola MSc 1; Olsen, Kirsty MSc 1; O'Brien, John T. DM 3
|
Institution: | (1) Institute for Ageing and Institute of NeuroscienceNewcastle UniversityNewcastle upon Tyne UK (2) Nuclear Medicine DepartmentNewcastle upon Tyne Hospitals National Health Service Foundation Trust, Newcastle upon TyneUK (3) Department of PsychiatryUniversity of CambridgeCambridge, UK
|
Title: | |
Source: | Movement Disorders. 33(7):1130-1138, July 2018.
|
Author Keywords: | Dementia with Lewy bodies; amyloid; positron emission tomography; florbetapir.
|
References: | 1. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65(12):1863-1872.
2. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006;67(11):1931-1934.
3. Donaghy P, Thomas AJ, O'Brien JT. Amyloid PET imaging in Lewy body disorders. Am J Geriatr Psychiatry 2015;23(1):23-37.
4. Lin KJ, Hsiao IT, Hsu JL, et al. Imaging characteristic of dual-phase (18)F-Florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment. Eur J Nucl Med Mol Imaging 2016;43(7):1304-1314.
5. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):263-269.
6. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017;89(1):88-100.
7. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006;21(11):1078-1085.
8. Lambon RMA, Powell J, Howard D, Whitworth AB, Garrard P, Hodges JR. Semantic memory is impaired in both dementia with Lewy bodies and dementia of Alzheimer's type: a comparative neuropsychological study and literature review. J Neurol Neurosurg Psychiatry 2001;70(2):149-156.
9. Sanchez-Cubillo I, Perianez JA, Adrover-Roig D, et al. Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc 2009;15(3):438-450.
10. McKenna P, Warrington EK. Graded Naming Test: Object Picture Book. 2nd rev. ed. Cambridge: Cambridge Cognition Ltd; 2007.
11. Rey A. L'Examen Clinique en Psychologie [The Clinical Examination in Psychology]. Paris: Presses Universitaires de France; 1964.
12. Wood JS, Firbank MJ, Mosimann UP, et al. Testing visual perception in dementia with Lewy bodies and Alzheimer disease. Am J Geriatr Psychiatry 2013;21(6):501-508.
13. Ballard C, O'Brien J, Gray A, et al. Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol 2001;58(6):977-982.
14. Landy KM, Salmon DP, Galasko D, et al. Motion discrimination in dementia with Lewy bodies and Alzheimer disease. Neurology 2015;85(16):1376-1382.
15. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9(3):179-186.
16. Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 1996;25(2):113-120.
17. D'Ath P, Katona P, Mullan E, Evans S, Katona C. Screening, detection and management of depression in elderly primary care attenders. I: the acceptability and performance of the 15 item Geriatric Depression Scale (GDS15) and the development of short versions. Fam Pract 1994;11(3):260-266.
18. Walker MP, Ayre GA, Cummings JL, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000;177:252-256.
19. Lee DR, McKeith I, Mosimann U, et al. The dementia cognitive fluctuation scale, a new psychometric test for clinicians to identify cognitive fluctuations in people with dementia. Am J Geriatr Psychiatry 2014;22(9):926-935.
20. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44(12):2308-2314.
21. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23(15):2129-2170.
22. Landau S, Jagust W. Florbetapir processing methods. adni.bitbucket.org. Accessed January 13, 2015.
23. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15(1):273-289.
24. Jagust WJ, Landau SM, Koeppe RA, et al. The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement 2015;11(7):757-771.
25. Della Rosa PA, Cerami C, Gallivanone F, et al. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics 2014;12(4):575-593.
26. O'Brien JT, Firbank MJ, Davison C, et al. 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy Body dementias. J Nucl Med 2014;55(12):1959-1965.
27. Firbank MJ, Barber R, Burton EJ, O'Brien JT. Validation of a fully automated hippocampal segmentation method on patients with dementia. Hum Brain Mapp 2008;29(12):1442-1449.
28. Eli Lilly . Amyvid (Florbetapir F 18 Injection): Highlights of Prescribing Information. Indianapolis: Eli Lilly; 2012.
29. Halliday GM, Song YJ, Harding AJ. Striatal beta-amyloid in dementia with Lewy bodies but not Parkinson's disease. J Neural Transm 2011;118(5):713-719.
30. Nelson PT, Kryscio RJ, Jicha GA, et al. Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology 2009;73(14):1127-1133.
31. Tiraboschi P, Attems J, Thomas A, et al. Clinicians' ability to diagnose dementia with Lewy bodies is not affected by beta-amyloid load. Neurology 2015;84(5):496-499.
32. Nedelska Z, Ferman TJ, Boeve BF, et al. Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging 2015;36(1):452-461.
33. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12(2):207-216.
34. Abdelnour C, van Steenoven I, Londos E, et al. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. Mov Disord 2016;31(8):1203-1208.
35. Ballard CG, Jacoby R, Del Ser T, et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies. Am J Psychiatry 2004;161(5):843-849.
36. Gomperts SN, Locascio JJ, Makaretz SJ, et al. Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol 2016;73(11):1334-1341.
37. Kantarci K, Lowe VJ, Boeve BF, et al. AV-1451 tau and beta-amyloid positron emission tomography imaging in dementia with Lewy bodies. Ann Neurol 2017;81(1):58-67.
38. Ishii K, Hosokawa C, Hyodo T, et al. Regional glucose metabolic reduction in dementia with Lewy bodies is independent of amyloid deposition. Ann Nucl Med 2015;29(1):78-83.
39. Kantarci K, Lowe VJ, Boeve BF, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012;33(9):2091-2105.
40. Sarro L, Senjem ML, Lundt ES, et al. Amyloid-beta deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain 2016;139(Pt 10):2740-2750.
41. Nedelska Z, Ferman TJ, Boeve BF, et al. Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging 2015;36(1):452-61.
42. Burton EJ, Barber R, Mukaetova-Ladinska EB, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 2009;132(Pt 1):195-203.
43. Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 2008;115(4):399-407.
44. Pletnikova O, West N, Lee MK, et al. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005;26(8):1183-1192.
45. Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003;300(5619):636-640.
46. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010;30(21):7281-7289.
47. Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 2015;313(19):1939-1949.
48. Hsiao IT, Huang CC, Hsieh CJ, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging 2012;39(4):613-620.
|
Language: | English.
|
Document Type: | Research Articles.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0885-3185
|
DOI Number: | https://dx.doi.org/10.1002/mds.2...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|